Developing two novel drugs to improving the lives of people with neurodevelopmental disabilities, with potential for first US marketing approval in Q1 2023.
View our Annual Reports

View Investor Presentations, Audio, Video

Visit our Shareholder Services

View Latest Investor Presentation
